ProPhase Labs Q2 net loss narrows to $4.5M, gross margin turns positive; patent for BE-Smart; crypto treasury approved

ProPhase Labs, Inc.

2025-Q2 EPS reported -$0.01 revenue$2,678,000

Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).
Gross margin improved to 58.9% from (10.3)% YoY; operating expenses cut 35% YTD; sale of PMI generated $8.7M gain.
U.S. patent granted for BE-Smart esophageal adenocarcinoma test in August 2025; accelerates commercialization.
Board approved crypto treasury strategy including Bitcoin; proposed authorized share increase to 1 billion for flexibility.
Stockholders' equity rose to $11.5M (from $7.4M at year-end); cash $169K; Crown Medical estimates $50M recovery.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.